NIOX - Ticker AI Digest

NIOX Group PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (NIOX) 1
NIOX 06:01
NIOX Group PLC
INTERIM RESULTS
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of NIOX Group PLC Interim Results for H1 2025**
NIOX Group PLC, a medical device company focused on asthma and COPD diagnosis and management, reported strong interim results for the six months ended June 30, 2025. Key highlights include
**Financial Performance**
* **Revenue Growth** 20% increase to £25.2 million (21% on a constant currency basis) compared to H1 2024.
* **Clinical Revenue** 8% growth to £20.0 million, driven by increased adoption of FeNO testing globally.
* **Research Revenue** 108% surge to £5.2 million, attributed to unforecasted increases in clinical trial activity using FeNO testing.
* **Adjusted EBITDA** 30% rise to £9.2 million, reflecting strong operational leverage and higher sales.
* **Adjusted EBITDA Margin** Improved to 36.5% from 33.8% in H1 2024.
* **Adjusted Basic Earnings per Share** Increased 31% to 2.26p.
* **Cash Position** Strong balance sheet with £11.8 million in cash as of June 30, 2025, despite a £5.0 million dividend payment in June.
**Operational Highlights**
* **Global Adoption of FeNO Testing** Continued penetration supported by new guidelines, tender wins, and expansion into Japanese community clinics.
* **Next-Generation Device** Development of NIOX PRO® on track for initial launch in late 2025.
* **US Market Strategy** Implementing a revised go-to-market strategy in the US, focusing on a hybrid model with a dedicated direct sales team and selected external partners.
**Outlook**
* **Strong Momentum** Trading in July and August continued on a strong trajectory, with research sales exceeding expectations.
* **Debt-Free Position** NIOX remains debt-free with £13.2 million in cash as of August 31, 2025.
* **Future Growth** The company is well-positioned for sustained revenue growth, strong cash generation, and attractive shareholder returns, driven by its core clinical business and strategic initiatives.
**Key Takeaways**
NIOX Group PLC demonstrated robust financial and operational performance in H1 2025, fueled by increasing adoption of FeNO testing and strong research demand. The companys focus on innovation, market expansion, and strategic partnerships positions it for continued growth and success in the respiratory diagnostics market.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
NIOX 06:01
NIOX Group PLC
INTERIM RESULTS
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of NIOX Group PLC Interim Results for H1 2025**
NIOX Group PLC, a medical device company focused on asthma and COPD diagnosis and management, reported strong interim results for the six months ended June 30, 2025. Key highlights include
**Financial Performance**
* **Revenue Growth** 20% increase to £25.2 million (21% on a constant currency basis) compared to H1 2024.
* **Clinical Revenue** 8% growth to £20.0 million, driven by increased adoption of FeNO testing globally.
* **Research Revenue** 108% surge to £5.2 million, attributed to unforecasted increases in clinical trial activity using FeNO testing.
* **Adjusted EBITDA** 30% rise to £9.2 million, reflecting strong operational leverage and higher sales.
* **Adjusted EBITDA Margin** Improved to 36.5% from 33.8% in H1 2024.
* **Adjusted Basic Earnings per Share** Increased 31% to 2.26p.
* **Cash Position** Strong balance sheet with £11.8 million in cash as of June 30, 2025, despite a £5.0 million dividend payment in June.
**Operational Highlights**
* **Global Adoption of FeNO Testing** Continued penetration supported by new guidelines, tender wins, and expansion into Japanese community clinics.
* **Next-Generation Device** Development of NIOX PRO® on track for initial launch in late 2025.
* **US Market Strategy** Implementing a revised go-to-market strategy in the US, focusing on a hybrid model with a dedicated direct sales team and selected external partners.
**Outlook**
* **Strong Momentum** Trading in July and August continued on a strong trajectory, with research sales exceeding expectations.
* **Debt-Free Position** NIOX remains debt-free with £13.2 million in cash as of August 31, 2025.
* **Future Growth** The company is well-positioned for sustained revenue growth, strong cash generation, and attractive shareholder returns, driven by its core clinical business and strategic initiatives.
**Key Takeaways**
NIOX Group PLC demonstrated robust financial and operational performance in H1 2025, fueled by increasing adoption of FeNO testing and strong research demand. The companys focus on innovation, market expansion, and strategic partnerships positions it for continued growth and success in the respiratory diagnostics market.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 1
NIOX 13:17
NIOX Group PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">TR1</mark> Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 3
NIOX 06:01
NIOX Group PLC
INTERIM RESULTS
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of NIOX Group PLC Interim Results for H1 2025**
NIOX Group PLC, a medical device company focused on asthma and COPD diagnosis and management, reported strong interim results for the six months ended June 30, 2025. Key highlights include
**Financial Performance**
* **Revenue Growth** 20% increase to £25.2 million (21% on a constant currency basis) compared to H1 2024.
* **Clinical Revenue** 8% growth to £20.0 million, driven by increased adoption of FeNO testing globally.
* **Research Revenue** 108% surge to £5.2 million, attributed to unforecasted increases in clinical trial activity using FeNO testing.
* **Adjusted EBITDA** 30% rise to £9.2 million, reflecting strong operational leverage and higher sales.
* **Adjusted EBITDA Margin** Improved to 36.5% from 33.8% in H1 2024.
* **Adjusted Basic Earnings per Share** Increased 31% to 2.26p.
* **Cash Position** Strong balance sheet with £11.8 million in cash as of June 30, 2025, despite a £5.0 million dividend payment in June.
**Operational Highlights**
* **Global Adoption of FeNO Testing** Continued penetration supported by new guidelines, tender wins, and expansion into Japanese community clinics.
* **Next-Generation Device** Development of NIOX PRO® on track for initial launch in late 2025.
* **US Market Strategy** Implementing a revised go-to-market strategy in the US, focusing on a hybrid model with a dedicated direct sales team and selected external partners.
**Outlook**
* **Strong Momentum** Trading in July and August continued on a strong trajectory, with research sales exceeding expectations.
* **Debt-Free Position** NIOX remains debt-free with £13.2 million in cash as of August 31, 2025.
* **Future Growth** The company is well-positioned for sustained revenue growth, strong cash generation, and attractive shareholder returns, driven by its core clinical business and strategic initiatives.
**Key Takeaways**
NIOX Group PLC demonstrated robust financial and operational performance in H1 2025, fueled by increasing adoption of FeNO testing and strong research demand. The companys focus on innovation, market expansion, and strategic partnerships positions it for continued growth and success in the respiratory diagnostics market.
NIOX 13:17
NIOX Group PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">TR1</mark> Buy
NIOX 14:42
NIOX Group PLC
Total Voting Rights

AI Crunch

Single-Ticker AI Crunch
NIOX signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for NIOX Group PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full NIOX AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for NIOX on 2025-09-30.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
238302448
Enterprise Value
146929695
Public Float
78.99
Broker Target
82
Shares Out
418074453
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BJVD3B28
Market
None
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
0.02
Ex Divi
2026-05-21
Earnings Date
2026-03-24
Net Debt
-18900000.0
Cash
19900000.0
EPS
0.02
Net Income
7000000.0
Revenue
48700000.0
Enterprise Value
146929695
Trailing PE
28.5
Forward PE
57.4713
Price Sales TTM
4.8933
Price Book MRQ
3.5252
EV Revenue
4.5052
EV EBITDA
14.34

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
27.2295
Institutions As Of
2026-03-24
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
1
Sale Director Dealing
9
Purchase TR1
5
Sale TR1
12
Broker Coverage Rows
0
Institution Holders Tracked
6
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit NIOX.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-09-30 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
NIOX Group PLC has fresh news flow feeding the chart narrative.
AI Charts Studio
NIOX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-09-30 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -27.69%
RSI Gauge
Price Change
AI Forecast